Health Canada approves Abbvie Skyrizi for treatment of adult patients with psoriasis

Recently, Us biotech giant AbbVie announced that Health Canada has approved Skyrizitoto for treatment of adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapymedication, Skyrizi was given the drug once in the 0th and 4th weeks, followed by a dose of 150mg (2 needles 75mg) and subcutaneous injections every 3 months (12 weeks)The approval is based on data from four key Phase III clinical studies (ultIMMa-1, ultIMMa-2, IMMvent, IMMhance)These studies were combined with more than 2,000 adult patients with moderate to severe plaque-type psoriasisThe results showed that Skyrizi treatment significantly improved skin psoriasis plaque removal after just 16 weeks of treatment and maintained plaque removal within one year (52 weeks) of treatmentThe approval also marks The world's second regulatory approval that Skyrizi has wonAt the end of March this year, Skyrizi was approved by Japan for the treatment of adult patients with plaque psoriasis, widespread pustules psoriasis (GPP), red skin psoriasis, and psoriasis arthritis that are inadequately responded to conventional therapySkyrizi is also under regulatory scrutiny in the United States and the European Unionthe U.S., theFDA(http://has designated a target date for the Prescription Drug User Charge (PDUFA) on April 25, 2019the EU, Skyrizi received positive approval in early March from the EuropeanMedicines(http://Authority (
http:// product (http:// committee for human medicine (http:// and is expected to be approved in the next two to three months